Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Umeclidinium in Adolescent Asthma
NCT01653483Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Sep 2012
- Primary completion
- Sep 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Umeclidinium with Placebo (2 arms). Primary endpoints: Subject safety as measured by adverse events and Subject safety as measured by serial ECGs and vital signs. Planned start Sep 2012; status: withdrawn.
02
Drugs
umeclidinium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01653483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653483.